Fortaz

Ceftazidime

Clinical data
Pronunciation	/sɛfˈtæzᵻdiːm/
Trade names	Fortaz, Tazicef, others
AHFS/Drugs.com	Monograph
MedlinePlus	a686007
Pregnancy category	AU: B1 US: B (No risk in non-human studies)
Routes of administration	intravenous, intramuscular, inhalation (off-label only)
ATC code	J01DD02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)
Pharmacokinetic data
Bioavailability	91% (IM)
Metabolism	negligible
Biological half-life	1.6–2 hours
Excretion	90–96% kidney
Identifiers
IUPAC name (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate
CAS Number	72558-82-8 Y
PubChem CID	5481173
DrugBank	DB00438 Y
ChemSpider	4587145 Y
UNII	DZR1ENT301
ChEBI	CHEBI:3508 Y
ChEMBL	CHEMBL201 N
ECHA InfoCard	100.112.489
Chemical and physical data
Formula	C22H22N6O7S2
Molar mass	546.58 g/mol
3D model (Jmol)	Interactive image
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=NOC(C(=O)O)(C)C)c3nc(sc3)N)C[n+]4ccccc4)C([O-])=O
InChI InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1 Y Key:ORFOPKXBNMVMKC-DWVKKRMSSA-N Y
NY (what is this?)

Ceftazidime, sold under the brand names Fortaz among others, is an antibiotic useful for the treatment of a number of bacterial infections. Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, pseudomonas aeruginosa infection, and vibrio infection. It is given by injection into a vein or muscle.

Common side effects include nausea, allergic reactions, and pain at the site of injection. Other side effects may include Clostridium difficile diarrhea. It is not recommended in people who have had previous anaphylaxis to a penicillin. Its use is relatively safe during pregnancy and breastfeeding. It is in the third-generation cephalosporin family of medications and works by interfering with the bacteria's cell wall.

Ceftazidime was patented in 1978 and came into commercial use in 1984. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Ceftazidime is available as a generic medication. The wholesale cost in the developing world is about 2.84 to 16.76 USD per day. In the United States a course of treatment costs 100 to 200 USD.